Side-by-side comparison of AI visibility scores, market position, and capabilities
AI antibody design platform targeting undruggable GPCRs and ion channels; $37M raised with $550M+ in AstraZeneca, BMS, and Takeda partnership milestones led by Radical Ventures.
Nabla Bio is a Harvard spinout biotech company using AI-driven generative protein design to develop antibodies against multipass membrane proteins — a class of drug targets including GPCRs (G protein-coupled receptors), ion channels, and transporters that are implicated in numerous diseases but have been historically undruggable with antibody therapies due to their complex 3D structure embedded in the cell membrane. A Y Combinator graduate, Nabla Bio raised $37 million total including a $26 million Series A led by Radical Ventures, and secured strategic collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda worth $550 million+ in upfront and milestone payments plus royalties.
UK private chef marketplace with 900+ chefs and $6.7M annualized revenue; 45-65% word-of-mouth growth backed by YC and Goodwater Capital expanding to US in 2025.
yhangry is a London-based marketplace connecting customers with 900+ private chefs for in-home dining experiences — enabling individuals, couples, and groups to book a professional chef who shops for ingredients, cooks a multi-course meal in the customer's kitchen, and handles cleanup, for occasions ranging from date nights to dinner parties and corporate events. Founded in 2022 and backed by Y Combinator, Goodwater Capital, and prominent angels with $3.5 million raised, yhangry achieved $6.7 million in annualized revenue in 2024 with 5,300+ bookings and prepares for US expansion in 2025.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.